Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical firm engaged in the discovery, development, manufacture, and sale of a wide range of medical products. The company operates facilities in the United States, Puerto Rico, and 25 other countries, distributing its products in approximately 135 countries worldwide. Eli Lilly specializes in various therapeutic areas, including neuroscience, cardiometabolic diseases, cancer, and immunology. Its key offerings include Verzenio for cancer treatment, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic conditions, as well as Taltz and Olumiant for immunological disorders. In addition to human health, the company conducts research aimed at treating diseases in animals and enhancing the efficiency of animal food production.

Andrew Adams

Group Vice President - Molecule Discovery and Director, Lilly Institutes of Genetic Medicine

Anat Ashkenazi

CFO

Gordon Brooks

Group Vice President - Controller and Corporate Strategy

Lotus Mallbris Ph.D

Vice President of Development and Immunology

Teresa Millan

Corporate Affairs Director

Diogo Rau

Executive Vice President and Chief Information and Digital Officer

Melissa Seymour

Executive VP of Global Quality

139 past transactions

Grove Biopharma

Series A in 2025
Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges, focused on the discovery and development of a novel class of “protein-like polymers” to treat significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Solu Therapeutics

Series A in 2025
Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

Augustine Therapeutics

Series A in 2025
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Ampersand Biomedicines

Series B in 2025
Ampersand Biomedicines is a biotechnology company that focuses on developing innovative therapeutic solutions aimed at treating diseases directly at the site of action. Utilizing its proprietary Address, Navigate, Design (AND)™ Platform, the company integrates a localizing element for precision targeting with an actuator tailored for specific disease modification. This approach allows for the exploration and treatment of a wide array of diseases across various areas of the body, enhancing the potential for effective medical interventions.

Maxion Therapeutics

Series A in 2025
Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

Insilico Medicine

Series E in 2025
Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

TRIMTECH Therapeutics

Seed Round in 2025
TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD).

Scorpion Therapeutics

Acquisition in 2025
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Orbis Medicines

Series A in 2025
Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Revisto

Seed Round in 2024
Revisto is a pioneering AI-powered technology that simplifies the medical, legal, and regulatory (MLR) review process for pharmaceutical marketing materials.

ProQR Therapeutics

Post in 2024
ProQR Therapeutics N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on the discovery and development of RNA-based therapeutics for genetic disorders. Founded in 2012, the company targets severe rare diseases, including Leber's congenital amaurosis type 10 and Usher syndrome type 2. ProQR's leading product candidates include sepofarsen, currently in a phase II/III clinical trial for Leber's congenital amaurosis 10, QR-421a in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa, QR-1123 in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, and QR-504a, which is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. The company has established license agreements with several prominent medical institutions, including General Hospital Corporation and Radboud University Medical Center.

Sunbird Bio

Venture Round in 2024
Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Aktis Oncology

Series B in 2024
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Amprion

Series B in 2024
Amprion is a biotechnology company based in San Francisco, California, established in 2007. The firm specializes in the diagnosis of neurodegenerative diseases, particularly focusing on conditions such as Parkinson’s disease, Alzheimer’s disease, and Lewy Body Dementia. Amprion develops innovative early detection technologies aimed at improving understanding of brain health. By leveraging personal biometrics and collective knowledge, the company seeks to enhance the ability of researchers and healthcare professionals to identify and understand these brain diseases, ultimately contributing to better patient outcomes and advancing the field of neuroscience.

NanoSyrinx

Series A in 2024
NanoSyrinx is a biotechnology company focused on developing an innovative system for the targeted delivery of therapeutic proteins and peptides directly into the cytosol of cells. By employing synthetic biology techniques, the company aims to create a groundbreaking method for drug delivery that enhances the efficacy, safety, and cost-effectiveness of treatments in the biopharmaceutical sector. This novel approach allows for precise delivery of therapeutic agents, potentially improving treatment outcomes for patients by ensuring that the drugs reach their intended cellular targets.

Superluminal Medicines

Series A in 2024
Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform quickly creates candidate-ready compounds using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. They leverage cutting-edge computational and machine-learning techniques to accelerate identifying and optimizing novel drug candidates. Their approach combines high-throughput experimental data with advanced algorithms to uncover therapeutic compounds faster and more efficiently than traditional methods.

OrsoBio

Series B in 2024
OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders, including obesity and related conditions such as type 2 diabetes and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways that maintain energy balance, thereby addressing the underlying causes of these disorders. OrsoBio's commitment to innovation seeks to revolutionize treatment options for individuals suffering from metabolic dysfunctions, including lipodystrophies and other obesity-associated complications. Through its research and development efforts, OrsoBio strives to enhance patients' energy metabolism and improve their overall health outcomes.

HAYA Therapeutics

Funding Round in 2024
HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Circle Pharma

Series D in 2024
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Ionetix

Venture Round in 2024
Ionetix Corporation specializes in the development, manufacturing, and distribution of superconducting cyclotrons designed for the point-of-care production of positron emission tomography (PET) radioisotopes. The company’s flagship product, the ION-12SC, is a PET radiopharmaceutical production system that generates N-13 ammonia, essential for myocardial perfusion imaging. Ionetix's compact cyclotron technology represents a significant advancement over traditional designs, offering advantages such as reduced size, weight, power requirements, and costs. The company installs and manages these systems to produce necessary doses of N-13 ammonia in proximity to imaging suites, thus enhancing operational efficiency in medical settings. Ionetix aims to provide healthcare providers with innovative tools and compounds that improve diagnostic capabilities and treatment options, particularly in the detection of coronary artery disease and the treatment of metastatic cancers. Founded in 2009, Ionetix is headquartered in San Francisco, California, with an additional facility in Lansing, Michigan.

RetiSpec

Series A in 2024
RetiSpec is developing a non-invasive eye scanner for early detection of Alzheimer’s Disease pathology years before symptoms occur, so that clinicians can intervene with emerging therapeutics early, when there’s a chance of actually impacting the disease.

Circle Pharma

Series D in 2024
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Augustine Therapeutics

Series A in 2024
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Radar Therapeutics

Seed Round in 2024
Radar Therapeutics pioneer in treatment modality, precision-expressed mRNA-based therapeutics.

Aktis Oncology

Corporate Round in 2024
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Lycia Therapeutics

Series C in 2024
Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

FireFly Bio

Series A in 2024
FireFly Bio focuses on developing Degrader Antibody Conjugates (DACs), a novel approach that merges the benefits of antibody-drug conjugates with selective protein degraders. This proprietary healthcare platform is designed to enhance cancer treatment by ensuring the precise delivery of therapeutic agents to targeted tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create more effective and targeted medicines that improve patient outcomes in the fight against cancer.

Prism BioLab

Series C in 2024
PRISM provider of a therapeutic treatment for non-oncology indications.The company develops therapeutic agents that are used to cure pulmonary fibrosis, cancer and incurable diseases.

UpDoc

Seed Round in 2024
UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Point Biopharma Global

Acquisition in 2023
POINT Biopharma Global Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of radioligand therapies for cancer treatment. The company is focused on creating a robust platform for the clinical development of radiopharmaceuticals, utilizing advanced radioisotopes such as Actinium-225 and Lutetium-177. POINT Biopharma's product pipeline includes several candidates, such as PNT2002, PNT2004, PNT2003, and PNT2001, among others. By leveraging a combination of innovative manufacturing technology and direct-to-patient targeting, POINT Biopharma aims to transform theragnostic drug development and enhance the commercialization of radioligands in the fight against cancer.

Yseop

Venture Round in 2023
Yseop is an artificial intelligence company specializing in natural language generation software tailored for various industries, including finance and life sciences. Its platform automates the creation of intelligent and non-repetitive text in multiple languages, enabling businesses to enhance efficiency and customer engagement. By utilizing a patented technology, Yseop streamlines tasks such as lead generation, report writing, and personalized proposals, allowing sales and marketing teams to focus more on customer interactions rather than administrative duties. This automation not only reduces operational costs but also improves the overall effectiveness of customer relations. Yseop offers its services through a Software as a Service (SaaS) model or as an annual license that can be hosted on a client’s servers, ensuring flexibility for its users. The software supports text generation in English, German, Dutch, French, Spanish, and Japanese, thereby catering to a global clientele.

Alto Neuroscience

Series C in 2023
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

ViaNautis

Series A in 2023
ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.

OrsoBio

Series A in 2023
OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders, including obesity and related conditions such as type 2 diabetes and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways that maintain energy balance, thereby addressing the underlying causes of these disorders. OrsoBio's commitment to innovation seeks to revolutionize treatment options for individuals suffering from metabolic dysfunctions, including lipodystrophies and other obesity-associated complications. Through its research and development efforts, OrsoBio strives to enhance patients' energy metabolism and improve their overall health outcomes.

Laverock Therapeutics

Seed Round in 2023
Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.

Sitryx Therapeutics

Series A in 2023
Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Mariana Oncology

Series B in 2023
Mariana Oncology is a biotechnology company focused on developing radiopharmaceuticals designed to target cancer cells using radioactive drugs. The company leverages expertise in ligand discovery, radiochemistry, and radiobiology, along with oncology translational and clinical research, to create a diverse pipeline aimed at treating various solid tumor types. By advancing the use of radiomedicines, Mariana Oncology seeks to enhance treatment options for medical professionals in their fight against cancer.

Amber Bio

Seed Round in 2023
Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations.

Versanis Bio

Acquisition in 2023
Versanis Bio is focused on discovering and developing medicines that target medical conditions commonly found in older adults. The company is advancing Bimagrumab, a human monoclonal antibody that inhibits activin type II receptors, blocking the action of ligands such as activin A and myostatin. Previous studies conducted by Novartis involved over 1,500 participants and demonstrated that Bimagrumab consistently induced significant fat loss while preserving lean mass. Additionally, the treatment has shown improvements in HbA1c levels and other cardiometabolic parameters, offering a promising option for overweight and obese adults aiming to achieve and maintain a healthier body composition.

Crossbow Therapeutics

Series A in 2023
Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies that mimic T-cells, which are essential components of the immune system, to target cancer cells with high precision. This next-generation approach allows for the assembly of immunotherapies that can reach previously inaccessible cancer cell targets, significantly broadening the scope of antibody therapy. By utilizing T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics aims to enhance the quality of life for cancer patients and unlock new therapeutic potentials across various types of cancer.

basys.ai

Pre Seed Round in 2023
Basys.ai is a company that specializes in automating prior authorization and utilization management for health plans and payers through an AI-driven platform. Its proprietary technology employs machine learning to digitize and encode payer policies, significantly reducing the time needed for implementation by up to nine months. The platform aims to enhance communication between patients and healthcare providers, streamline administrative processes, and improve patient outcomes. By focusing on a data-centric approach, Basys.ai helps organizations optimize care delivery while minimizing costs associated with administrative tasks and medical procedures.

Emergence Therapeutics

Acquisition in 2023
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

Sigilon Therapeutics

Acquisition in 2023
Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing functional cures for chronic diseases. The company’s lead product candidate, SIG-001, is currently in Phase I/II clinical trials aimed at preventing bleeding episodes in patients with moderate to severe Hemophilia A. In addition to SIG-001, Sigilon is working on SIG-005, which targets the non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells in the treatment of type 1 diabetes. Utilizing its Shielded Living Therapeutics platform, Sigilon aims to create immune-protected, engineered human cells that restore normal physiological functions while minimizing issues of fibrosis and immune rejection. The company was founded in 2015 and adopted its current name in June 2017.

AltPep

Series B in 2023
AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their challenging nature. The company operates a proprietary peptide-based platform designed to identify and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic and therapeutic applications, particularly focused on the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By enabling healthcare institutions to detect and address amyloid diseases at an earlier stage, AltPep aims to enhance human health outcomes and improve treatment options for patients suffering from these conditions.

DICE Therapeutics

Acquisition in 2023
DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Verve Therapeutics

Post in 2023
Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Diogenx

Series A in 2023
DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.

Therini Bio

Series A in 2023
Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.

Volastra

Series A in 2023
Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

IgGenix

Series B in 2023
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

ProQR Therapeutics

Post in 2022
ProQR Therapeutics N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on the discovery and development of RNA-based therapeutics for genetic disorders. Founded in 2012, the company targets severe rare diseases, including Leber's congenital amaurosis type 10 and Usher syndrome type 2. ProQR's leading product candidates include sepofarsen, currently in a phase II/III clinical trial for Leber's congenital amaurosis 10, QR-421a in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa, QR-1123 in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, and QR-504a, which is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. The company has established license agreements with several prominent medical institutions, including General Hospital Corporation and Radboud University Medical Center.

Rezo Therapeutics

Series A in 2022
Rezo Therapeutics is a biotechnology company that focuses on developing precision therapeutics by mapping disease networks. Utilizing its proprietary Sequence to Systems to Drugs (SSD) platform, Rezo integrates various technologies, including proteomics, genetics, structural biology, chemistry, and bioinformatics, to create comprehensive molecular maps of diseases. This innovative approach enhances the identification of novel targets and therapies, particularly in oncology, where Rezo initially concentrates its efforts. The company aims to expand its therapeutic focus through collaborations and partnerships, positioning itself at the forefront of advancing treatment options across multiple disease areas.

Akouos

Acquisition in 2022
Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

XellSmart

Series A in 2022
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Artax Biopharma

Venture Round in 2022
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Arkuda Therapeutics

Series B in 2022
Arkuda Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company focuses on developing innovative medicines for patients suffering from neurological diseases, particularly targeting neurodegenerative conditions. Arkuda leverages insights into progranulin and lysosomal biology to create therapies aimed at addressing progranulin deficiency and lysosomal dysfunction, specifically in genetically-defined frontotemporal dementia related to mutations in the GRN gene. Its lead compounds are designed to improve cellular health in the brain, with the goal of delaying disease progression and the onset of symptoms.

Iterative Scopes

Series B in 2022
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.

Verge Genomics

Series B in 2021
Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Regor Therapeutics

Venture Round in 2021
Regor Therapeutics is a clinical-stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.

Mozart Therapeutics

Series A in 2021
Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Genedit

Series A in 2021
GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

Vanqua Bio

Series B in 2021
Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients suffering from neurodegenerative diseases. The company leverages a technology platform that incorporates human genetics and patient-derived neuronal cells to identify and validate new disease pathways linked to lysosomal dysfunction and the inappropriate activation of the innate immune system. Vanqua Bio focuses on creating small-molecule activators of glucocerebrosidase and advancing programs that target the innate immune system, with the aim of addressing the progression of various neurological disorders. Through its efforts, the company seeks to provide healthcare professionals with transformative treatment options for patients facing these challenging conditions.

Lycia Therapeutics

Series B in 2021
Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

Iterative Scopes

Series A in 2021
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.

Protomer Technologies

Acquisition in 2021
Protomer Technologies operates as a pre-clinical stage biotechnology company. Its research and technology development efforts are currently focused on metabolic diseases. The company was founded in 2014 and is headquartered in Pasadena, California.

MiNA Therapeutics

Corporate Round in 2021
MiNA Therapeutics is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing small activating RNA medicines aimed at restoring normal cell function in patients. Established in 2008, the company is advancing its pipeline with products such as MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA in conjunction with Pembrolizumab for advanced solid tumors. MiNA's innovative approach leverages gene activation mechanisms to transform the treatment landscape for cancer and other serious diseases, enabling healthcare professionals to better address these conditions.

TRex Bio

Series A in 2021
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Strateos

Series B in 2021
Strateos is a company that specializes in automating laboratory processes in chemistry, biology, and tissue analysis through its advanced robotic cloud laboratory platform. By integrating cutting-edge robotics with sophisticated software for imaging and analytics, Strateos provides pharmaceutical partners with the tools to accelerate drug discovery and development. The company emerged from a merger between Transcriptic, which pioneered on-demand robotic lab services, and 3Scan, known for its automation and machine learning capabilities in tissue analysis. Strateos aims to streamline the drug discovery process by offering a comprehensive suite of technologies that transform life science methods into data-driven solutions. This approach not only enhances productivity and efficiency but also redefines the traditional research model, making it more accessible and effective for scientists. Through its innovative platform, Strateos positions itself as a valuable partner in the life sciences sector, focusing on delivering significant time and cost savings in the drug development process.

Jaguar Gene Therapy

Series B in 2021
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

DTx Pharma

Series B in 2021
DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.

Evox Therapeutics

Series C in 2021
Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

Seraxis

Series C in 2021
Seraxis is a biotechnology company founded in March 2013, with operations in Singapore and the United States, and a GMP lab located in Germantown, Maryland. The company specializes in developing innovative cell and encapsulation technologies aimed at creating a practical cell therapy for insulin-dependent diabetes. Their primary objective is to provide a long-term cure for diabetic patients that eliminates the need for immunosuppression, thereby improving the management of glucose levels through the production of insulin. Seraxis is structured to expedite the development of this therapy while maximizing value for its shareholders.

Auron Therapeutics

Seed Round in 2021
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Blacksmith Medicines

Seed Round in 2021
Blacksmith Medicines specializes in developing therapeutics that target metal-dependent enzymes, which constitute over 30% of known enzymes in human physiology. Their innovative platform focuses on metalloenzyme chemistry to create medicines aimed at addressing immuno-oncology and inflammatory diseases. By leveraging a specialized library of metal-binding pharmacophores alongside proprietary computational modeling techniques, Blacksmith Medicines efficiently designs small molecule inhibitors that interact with essential metal ions such as magnesium, zinc, iron, manganese, and copper in the enzymes' active sites. This approach allows for the rapid and predictable development of potent and selective inhibitors, enhancing the potential for effective treatments in various medical fields.

Terns Pharmaceuticals

Series C in 2021
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

Prevail Therapeutics

Acquisition in 2020
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.

Faze Medicines

Series A in 2020
Faze Medicines is a biotechnology company founded in 2020 and located in Cambridge, Massachusetts. The company focuses on developing small molecule drugs that target the underlying mechanisms of disease pathology, with initial therapeutic efforts directed towards conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines employs advanced screening and proteomics techniques to explore biomolecular condensate interaction networks, which aids in the identification and development of novel therapeutics. Through its innovative approach, Faze aims to provide effective treatments for patients suffering from these challenging diseases.

Centrexion Therapeutics

Venture Round in 2020
Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing non-opioid and non-addictive therapies aimed at addressing chronic pain. The company's product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, and in Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain associated with inflammatory, neuropathic, and mixed conditions. Other candidates under development include CNTX-6970, for inflammatory pain, and CNTX-2022, a high-concentration topical gel formulation of lidocaine for various types of pain. CNTX-6016 is also in pre-clinical stages focusing on chronic neuropathic pain. Founded in 2013, Centrexion Therapeutics aims to provide safe and effective solutions for patients suffering from chronic pain conditions.

Disarm Therapeutics

Acquisition in 2020
Disarm Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for patients suffering from neurological diseases. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company aims to create disease-modifying drugs that prevent axonal degeneration, which is a key factor in various neurological disorders. Disarm's portfolio addresses conditions such as multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies, providing potential treatments for acute diseases affecting the central, ocular, and peripheral nervous systems. As of late 2020, Disarm Therapeutics operates as a subsidiary of Eli Lilly and Company.

Cedilla Therapeutics

Series B in 2020
Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation. The company was founded in 2018 and based in Cambridge, Massachusetts.

Nido Biosciences

Venture Round in 2020
Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company utilizes a functional genomics discovery platform based on human cell lines to identify novel therapeutic targets, addressing the underlying biology of neurodegenerative diseases. By leveraging advancements in neuroscience and human genetics, Nido aims to create precise medications that restore healthy cell function and improve treatment options for conditions that significantly impact patient quality of life.

AbCellera

Series B in 2020
AbCellera is an antibody discovery and development company focused on overcoming the limitations of traditional discovery methods. By utilizing its integrated platform, AbCellera's experts rapidly search a diverse array of antibodies to identify the most effective candidates for clinical development. This streamlined approach allows for faster movement to clinical trials, ultimately benefiting patients sooner. The company has a strong track record of collaborating with both emerging biotechnology firms and established pharmaceutical companies, providing optimized solutions tailored to their needs. AbCellera employs proprietary technology and advanced data science to enhance its antibody discovery process, positioning itself as a strategic partner in the biopharmaceutical industry.

Sitryx Therapeutics

Corporate Round in 2020
Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Sigilon Therapeutics

Series B in 2020
Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing functional cures for chronic diseases. The company’s lead product candidate, SIG-001, is currently in Phase I/II clinical trials aimed at preventing bleeding episodes in patients with moderate to severe Hemophilia A. In addition to SIG-001, Sigilon is working on SIG-005, which targets the non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells in the treatment of type 1 diabetes. Utilizing its Shielded Living Therapeutics platform, Sigilon aims to create immune-protected, engineered human cells that restore normal physiological functions while minimizing issues of fibrosis and immune rejection. The company was founded in 2015 and adopted its current name in June 2017.

Immunocore

Series B in 2020
Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Dermira

Acquisition in 2020
Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

DTx Pharma

Series A in 2020
DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.

Avidity Biosciences

Series C in 2019
Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

Avidity Biosciences

Venture Round in 2019
Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

Loxo Oncology

Acquisition in 2019
Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.

Dicerna Pharmaceuticals

Post in 2018
Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Rimidi

Series A in 2018
Rimidi Inc. is a healthcare technology company based in Atlanta, Georgia, focused on improving diabetes management for patients and healthcare providers. Founded in 2011, the company offers a cloud-based software solution known as DIABETES+ME, which integrates patient-generated health data from connected devices with clinical data to provide personalized insights. This platform allows patients and physicians to identify gaps in diabetes management and outlines the necessary steps to address these gaps, ultimately helping to meet patient health targets and enhance the care cycle. By facilitating remote monitoring and enabling clinicians to make timely adjustments in treatment, Rimidi aims to address one of healthcare's most pressing challenges: diabetes.

Aurka Pharma

Acquisition in 2018
AurKa Pharma is a biopharmaceutical company focused on developing a single compound aimed at treating solid tumors. The company has completed GLP toxicology studies for its drug candidate and is preparing to initiate clinical development. Once it receives the necessary regulatory approvals, the compound will be tested in clinical settings to determine its efficacy in treating solid tumors. AurKa Pharma intends to explore additional cancer indications after establishing proof-of-concept, ultimately aiming to enhance treatment options for cancer patients.

Sigilon Therapeutics

Series A in 2018
Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing functional cures for chronic diseases. The company’s lead product candidate, SIG-001, is currently in Phase I/II clinical trials aimed at preventing bleeding episodes in patients with moderate to severe Hemophilia A. In addition to SIG-001, Sigilon is working on SIG-005, which targets the non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells in the treatment of type 1 diabetes. Utilizing its Shielded Living Therapeutics platform, Sigilon aims to create immune-protected, engineered human cells that restore normal physiological functions while minimizing issues of fibrosis and immune rejection. The company was founded in 2015 and adopted its current name in June 2017.

Entrega Bio

Venture Round in 2017
Entrega Bio offers a proprietary technology that makes injectable substances available orally. Its technology has the potential to deliver a wide variety of biological molecules, drug substances, and nanoparticles. Entrega Bio collaborates with pharma and non-pharma industry partners to develop the platform for innovative therapeutic and diagnostic modalities. This platform enables novel applications in a variety of fields such as disease management and tracking in the burgeoning mobile health arena. Entrega Bio is based in Boston, Massachusetts, United States.

Rodeo Therapeutics

Series A in 2017
Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.

CoLucid Pharmaceuticals

Acquisition in 2017
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

ApoGen Biotechnologies

Series A in 2016
ApoGen Biotechnologies, Inc., founded in 2014 and located in Seattle, Washington, is dedicated to developing innovative therapeutics aimed at addressing the challenges of cancer treatment, particularly the issue of drug resistance. The company focuses on targeting the key drivers of genomic mutations in cancer cells, which are central to tumor evolution and the development of resistance to existing therapies. By addressing the chronic mutations in cancer genomes, ApoGen aims to improve treatment efficacy, reduce cancer recurrence and metastasis, and enhance overall patient survival. The company's approach represents a shift from traditional therapies, providing new hope in the ongoing battle against cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.